Gene panel market to reach USD 5.4B from 2024-28

The global gene panel market size is estimated to grow by USD 5.40 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 23.44% during the forecast period. Growing use of gene panels in cancer-targeted therapies is driving market growth, with a trend towards collaboration to maximize research efficiency. However, large ngs gene panel implementation issues poses a challenge.

Key market trends fueling growth
The global life sciences tools and services market is experiencing pressure to lower costs, leading vendors to form strategic alliances along the value chain. In the gene panel market, this trend is evident with an increase in collaborations between vendors and academic institutions. Agilent Technologies Inc., a major player in gene panels, recently signed an MOU with Theragen Bio in South Korea. Under this agreement, Agilent and Theragen Bio will combine their expertise in software development, engineering, and cancer genomic profiling design to advance localized analysis capabilities and expedite treatment decisions. Agilent’s SureSelect Cancer Gene Panel test, which utilizes next-generation sequencing to minimize hands-on time and maximize lab efficiency, is expected to help research organizations and vendors overcome gene panel development challenges, contributing to the market’s growth.

Gene panels are becoming a significant trend in the healthcare industry, particularly in oncology where genetic alterations play a crucial role in cancer diagnosis and treatment. With rising cancer rates, personalized medicine based on genetic composition is gaining importance. Data analysis of genetic information is key to standardizing diagnostics services and enabling early screening for various diseases. Laboratories offering gene panels for oncology, carrier screening, pharmacogenomics, and chronic diseases are in high demand. Reimbursement policies and insurance coverage are crucial considerations for the clinical value of these tests. Evidence-based diagnostic panels, such as cancer panels and next-generation sequencing panels, help clinicians in disease prognostics and therapeutics. Genetic predisposition to fatalities from diseases like cardiovascular diseases, diabetes, arthritis, and multiple chronic conditions can be identified through gene panels. Early screening for diagnosed genetic conditions and monogenic defects is essential for risk factor management and improving mortality rates. Gene panels are valuable tools for clinicians in various therapeutic areas, including hereditary disorders and chronic diseases.

Research analysis
Gene panels are a set of tests that analyze multiple genes associated with specific hereditary disorders, monogenic defects, and genetic predispositions to various diseases. These disorders include, but are not limited to, hereditary cancers, cardiovascular diseases, diabetes, arthritis, and other chronic conditions. The mortality rate for many of these conditions can be significantly reduced through early diagnosis and personalized therapeutic interventions. Clinicians use gene panels for disease prognostics and to identify genetic alterations that may contribute to an individual’s risk for multiple chronic conditions. Genomics and sequencing technologies have made gene panels more accessible and affordable, leading to increased use in oncology, genetics, and other therapeutic areas. Test kits for genetic screening are widely available for adults and can provide valuable information for disease prevention and management. Gene panels play a crucial role in the diagnosis and treatment of genetic disorders and can help improve patient outcomes. Cancer rates continue to rise, making genetic testing an essential tool for identifying individuals at high risk and providing opportunities for preventative measures. Personalized medicine, which takes into account an individual’s genetic composition, is becoming increasingly important in the healthcare industry, and gene panels are a key component of this approach.

Market research overview
Gene panels are a crucial advancement in the field of genetics, offering comprehensive analysis of multiple genes associated with various hereditary disorders and cancer. These panels help in identifying genetic predispositions, enabling early screening, disease prognostics, and therapeutic regimes for diagnosed genetic conditions. Hereditary disorders encompass a wide range of monogenic defects, including Down syndrome, and cancer, which have significant mortality rates and incidence rates. Gene panels are designed to detect genetic discrepancies through methods such as methylation microarray, genotyping, and next-generation sequencing. Clinicians utilize gene panels to assess cancer risk, diagnose congenital diseases and disorders, and provide personalized medicine. Pre-designed gene panels are available for specific disorders, while customizable ones cater to individual needs. Biomarkers, tumor genes, and genomic signatures are essential components of gene panels, providing valuable insights into disease progression and therapeutic responses. Major applications of gene panels include cancer risk assessment, pre-gestational screening, prenatal screening, and neonatal screening. Technologies such as Illumina, CRISP validation, and NGS panels are integral to gene panel development. Hospitals and diagnostic laboratories are significant end-users of gene panels, with reimbursement policies and insurance coverage playing a crucial role in their adoption. Gene panels offer significant clinical value, with evidence-based data analysis and standardization being essential for their successful implementation. The market for gene panels is vast, including test kits segment, amplicon-based approach, hybridization approach, and next-generation sequencing. Rare disorders, hereditary cancer panels, and pharmacogenomic panels are other significant segments within the gene panel market. In conclusion, gene panels represent a significant advancement in the field of genetics, offering comprehensive genetic screening, early detection, and personalized therapeutic regimes for various hereditary disorders and cancer. The market for gene panels is vast and diverse, with numerous applications, technologies, and end-users contributing to its growth. Technavio